001). Osteoporosis appears to increase the resorption of the middle ear ossicles, a process that can be avoided with zoledronic acid administration. Prevention of the effects of osteoporosis in humans may help decrease the irreversible changes in the middle ear ossicles.
Introduction
Hearing loss is the fourth most commonly reported chronic condition in the elderly; it has been reported that approximately 30% of persons older than 65 years and 50% of those older than 75 years experience some degree of hearing loss. 1, 2 Hearing function in older adults may be related to bone health, and hearing sensitivity may be adversely affected by osteoporotic bone loss.
Despite the prevalence of age-related hearing loss, little progress has been made in identifying its etiology. Demineralization of the petrous temporal bone, including the cochlear capsule and/or the internal auditory canal, in conjunction with age-related loss of bone mass may be biologic factors contributing to hearing loss in the elderly. 3 The relationship between hearing loss and bone pathology of the skull has been explored primarily in studies of patients with Paget disease of bone and cochlear otosclerosis. 4, 5 Some studies have found that demineralization of the cochlea and otic capsule was associated with sensorineural hearing loss, and that the degree of cochlear demineralization corresponded directly to the severity of the hearing loss. 4, 6 Although the etiologies of Paget disease of bone and cochlear otosclerosis are different from that of osteoporosis, we suggest that there is a generalized mechanism by which hearing and osteoporosis might be related. We found no specific literature relating to a bone mass of the appendicular skeleton occurring simultaneously with that of the temporal bone, but there is some evidence that osteoporosis does not spare the bones of the skull.
Bisphosphonates are the most frequently prescribed medications for the treatment of osteoporosis. 7 Bisphosphonates are pyrophosphate analogs that are covered with a phosphate-carbon-phosphate bond, which is stable to chemical and enzymatic hydrolysis. These drugs strongly bind to hydroxyapatite crystals and potently inhibit osteoclast-mediated bone resorption while minimally inhibiting osteoblast activity. 8, 9 Of all the bisphosphonates, zoledronic acid, a strongly effective third-generation intravenous agent, exhibits the greatest affinity for bone mineral with the longest retention, which allows it to be dosed only once a year for the treatment of osteoporosis.
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A few studies have been conducted that evaluated the effects of bisphosphonates on implant osseointegration in osteoporotic animal models. These studies showed that systemic administration of alendronate and ibandronate and local delivery of pamidronate and zoledronic acid improved healing and osseointegration in estrogen-deficient bones. 9, [11] [12] [13] [14] [15] [16] For example, Narai and Nagahata evaluated the effect of alendronate on titanium implant osseointegration in an ovariectomized rat model. 11 They found that alendronate improved the mechanical stability of implants placed in estrogendeficient bone.
We describe our study to investigate the effect of osteoporosis on the middle ear ossicles and to reverse these changes with zoledronic acid in rabbits.
Material and methods
Nineteen female New Zealand white rabbits aged 6 to 12 months and weighing 2 to 4 kg were included in this study. They were housed 1 per cage and fed with standard rabbit chow and tap water ad libitum. The rabbits were divided into three groups: one group consisted of 6 rabbits with osteoporotic ears who were treated with zoledronic acid; the second group was made up of 8 rabbits with osteoporotic ears who were not treated; a control group included 5 rabbits with normal ears who underwent no interventions.
Laparotomy with general anesthesia was performed to remove the ovaries in all rabbits but the controls; the controls underwent only a skin incision and suturation without any abdominal intervention. In the zoledronic acid group, the drug was administered intravenously by infusion pump at a single dose of 0.1 mg/kg diluted with 10 ml of physiologic serum.
Sixteen weeks after oophorectomy, the rabbits were sacrificed with administration of 22.5% potassium chloride applied via the intracardiac route under ketamine (40 mg/kg) and xylazine (5 mg/kg) anesthesia. Next, a retroauricular incision was made, a tympanomeatal flap was elevated, and the posterosuperior external auditory canal walls were removed bilaterally to increase exposure of the ossicles to microscopic examination.
The mallei, incudes, and stapes were carefully removed from the middle ear cavities of each rabbit for examination of the morphology of the auditory ossicles. The ossicles were placed in a formaldehyde solution and transferred to the pathology department. The bones were embedded in paraffin and serially sectioned at a thickness of 12 µm. After the staining of every 20th section with hematoxylin and eosin and van Gieson stain, two pathologists who were blinded to the origin of the specimens examined the sections by light microscopy.
Bone resorption and increased osteoblastic activity of the auditory ossicles were scored quantitatively as positive if there was osteoblastic activity (even in a small area) and negative if there was no osteoblastic activity.
Statistical analysis. Statistical analysis was performed with the Statistical Package for the Social Sciences software (v. 20.0). Categorical variables among groups were analyzed with the chi-square test or Fisher exact test. A fourfold table was applied to calculate the odds ratio (OR) and 95% confidence interval (CI). A p value of <0.05 was considered statistically significant.
Ethical considerations. The experimental protocol was designed in accordance with the Guide for the Care and Use of Laboratory Animals. 17 The study was performed with approval from the Committee on Animal Research of Çukurova University in Adana, Turkey.
Results

Zoledronic acid group.
We observed an increase in the number of blood vessels and osteoblasts on the rim of the bone within the normal bone structure in the ossicles of 8 of the 12 ears (66.7%). In the remaining 4 ears, osteoclasts and osteoblasts were noted on the rim of the bone, and this was regarded as a mild degree of osteoporosis ( figure 1) .
Untreated osteoporosis group. When the 16 middle ear ossicles of the untreated oopherectomized rabbits were compared with those of the control group, they exhibited no clear decline in mineralized bone mass. While 15 of the ossicles (93.8%) exhibited features of focal or generalized bone resorption, hypercellularity was seen on the rim of the bones, a sign of bone remodeling ( figure 2, A) . In addition, active osteoblasts, capillary blood vessels ( figure 2, B) , and some multinucleated osteoclasts (figure 2, C) were noticed. On H and E staining, a deposition of eosinophilic substance was observed on the osteoblastic rim, particularly as red on van Gieson staining. In some areas of the bone, cavitary lesions integrated the middle ear air space. Most of the auditory ossicles showed erosion on the articulated faces. The presence of a focal or generalized resorption of bone demonstrated in the ossicles was considered to represent moderate to severe osteoporosis.
Control group. None of the control ears showed any evidence of ossicle remodeling, nor was osteoclastic activity detected in their bone. The ossicles were intact without any areas of bone resorption.
Group comparisons. The difference in the incidence of osteoporosis between the zolendronic acid group and the untreated osteoporosis group was statistically significant (33.3 vs. 93.8%; p < 0.001) (table).
Discussion
We found that the ossicles of the untreated oopherectomized rabbits demonstrated clear evidence of a progressive and abnormal remodeling process and bone resorption that was not observed in the controls. A notable feature was the occurrence of focal hypercellular areas that exhibited bone resorption and deposition and resembled the lesions of active otosclerosis. 7 This resemblance might have been the result of an increased rate of bone remodeling.
Even though a clear decline in mineralized bone mass was not determined in the untreated osteoporotic ears vis-à-vis the control ears, 15 of 16 (93.8%) osteoporotic ossicles showed features of focal or generalized bone resorption. We noted an especially extensive resorption of the malleus processus brevis and elevation of osteoclastic bone resorption in the auditory ossicles in the untreated osteoporotic rabbits.
It is not possible to comment on whether certain areas within each ossicle were preferentially resorbed. Furthermore, some of the auditory ossicles in the untreated osteoporotic ears showed erosion on the articulated face. In some areas of the bone in these ears, cavitary lesions integrated the middle ear air space. We could speculate that these changes in the ossicles on light microscopy may have an adverse effect on hearing, but the influence of these findings on hearing levels needs to be determined by future studies.
The association between hearing loss and osteoporosis is controversial. Although such a link has been suggested, 3 two epidemiologic studies found no correlation in elderly women. 18, 19 Another study found that women with hearing loss had less bone mineral density (BMD) than did women with normal hearing, although the difference was not statistically significant. 20 In bone remodeling, BMD is maintained by a coupling of osteoclastic bone resorption with subsequent osteoblastic formation. 21 Demineralization of the cochlear capsule and/or the internal 
Figure 2. A: In the untreated osteoporosis group, hypercellularity is seen on the rim of the bones, a sign of bone remodeling (H and E, original magnification ×40). B: Active osteoblasts and capillary blood vessels are seen (×200). C: Multinucleated osteoclasts (arrows) are present (×400).
auditory canal has been associated with hearing loss, and the degree of hearing loss has been directly related to the degree of demineralization in the otic capsule. 21 The presence of hearing loss has been found to increase the risk of developing low femoral BMD. 3 Osteoprotegerin is a key regulator of bone metabolism that inhibits the differentiation, survival, and fusion of osteoclastic precursor cells, suppresses activation, and promotes apoptosis of osteoclasts. Zehnder et al reported that osteoprotegerin is highly expressed in cochlear soft tissues and secreted into the perilymph and surrounding bone in mice. 22 Kanzaki et al observed erosion of the malleus, incus, and stapes, as well as stapedial fixation in adult osteoprotegerin-/-mice. 23 They also detected a progressive hearing loss beginning at 6 to 15 weeks of age. They concluded that osteoprotegerin plays a critical role in maintaining the quality of bone conduction by protecting the auditory ossicles and otic capsule from bone resorption.
Even though the epidemiologic studies could not demonstrate clear evidence of an association between hearing loss and osteoporosis, animal studies have supported the association. We found a progressive and abnormal remodeling process and bone resorption in our first two groups that was not observed in the control rabbits. The effect of this osteoclastic activity and the effect of osteoprotegerin on hearing need to be determined in future studies.
Although both the radius and the femoral neck are made primarily of cortical bone, the femoral neck contains a relatively high percentage of trabecular (cancellous) bone. The temporal bone is also made up primarily of cancellous bone. 24 In future studies, the inclusion of a third bone site such as the lumbar region of the spine, which contains a high proportion of trabecular bone, would help to clarify the association between hearing loss and bone mass. A direct association assumes that measured bone mass of the femur neck reflects the amount of bone mass in the petrous temporal bone and that demineralization of the petrous temporal bone is related to sensorineural hearing loss.
Bone demineralization of the petrous temporal bone, including the cochlea and otic capsule, has been related to hearing loss in other metabolic bone diseases, 4, 5 and bone demineralization of the skull has been documented in persons with severe osteoporosis. 25 Although several agents are available to treat osteoporosis and osteoblastic activity, their relative efficacy and toxicity when used to prevent fractures has not been well described. Bisphosphonates play a central role in the management of bone loss secondary to a range of disorders, including metastatic bone disease, cancer-treatment-induced bone loss, and postmenopausal osteoporosis. Zoledronic acid increases osteoblastic activity in the ossicles.
Our study found that histologic changes seen in osteoporosis of the middle ear ossicles of rabbits were reversed with zoledronic acid in 66.7% of ears. The ossicles of untreated osteoporotic ears demonstrated clear evidence of a progressive and abnormal remodeling process and bone resorption, changes that can be reversed with zoledronic acid. 
